Literature DB >> 17713549

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

B Cassinat, C Laguillier, C Gardin, V de Beco, S Burcheri, P Fenaux, C Chomienne, J-J Kiladjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17713549     DOI： 10.1038/sj.leu.2404908

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Carme Pedro; Francesc García-Pallarols; Luz Martínez-Avilés; Beatriz Bellosillo; Carlos Besses
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 2.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 3.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

4.  Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Authors:  Nabih Maslah; Juliette Soret; Christine Dosquet; Laetitia Vercellino; Célia Belkhodja; Marie-Hélène Schlageter; Bruno Cassinat; Jean-Jacques Kiladjian; Christine Chomienne; Stephane Giraudier
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

Review 5.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

6.  Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Authors:  Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

Review 7.  Novel and emerging therapies for the treatment of polycythemia vera.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Expert Rev Hematol       Date:  2014-10-29       Impact factor: 2.929

8.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

Review 9.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 10.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.